On Monday, H.C. Wainwright maintained a Buy rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a steady price target of $64.00. The firm's confidence in the stock is rooted in the anticipated durable top-line revenue growth from sales of IMCIVREE (setmelanotide), especially in niche obesity indications.
The firm has updated its revenue forecasts ahead of the third-quarter financial results for 2024, adjusting the full-year 2024 revenue projection to $123.2 million, a decrease from the previously estimated $129.3 million. Similarly, the full-year 2025 revenue forecast has been updated to $178.5 million from the prior $187.6 million.
The firm also adjusted its bottom-line estimates, with the full-year 2024 net loss projection now at $4.42 per share, compared to the earlier estimate of a $4.33 per share loss. For 2025, the net loss expectation has been revised to $2.56 per share from the previous forecast of a $2.26 per share loss. These revisions take into account a slightly greater market penetration and modestly lower pricing that align with the current market conditions.
Moreover, H.C. Wainwright has increased the probability of approval for IMCIVREE in treating hypothalamic obesity (HO) to 65%, up from the previous 60%. This adjustment reflects the firm's opinion that this represents a risk-mitigated opportunity for Rhythm Pharmaceuticals. Despite the revised forecasts, the firm's long-term outlook remains positive, as indicated by the reiterated Buy rating and 12-month price target of $64.
In other recent news, Rhythm Pharmaceuticals reported significant developments. The company's annual meeting of stockholders resulted in the re-election of three Class I Directors and approval of all proposals, demonstrating stockholders' confidence in the company's leadership. Rhythm Pharmaceuticals also achieved robust Q2 2024 results, with earnings reaching $29.1 million, primarily driven by sales of its drug, Imcivree.
The U.S. Food and Drug Administration (FDA) accepted Rhythm Pharmaceuticals' supplemental New Drug Application (sNDA) for Imcivree to extend treatment to younger children with certain genetic obesity disorders. This development underscores the company's commitment to expanding its therapeutic offerings.
In the realm of financial analysis, JMP Securities initiated coverage on Rhythm Pharmaceuticals with a Market Outperform rating, signifying positive expectations for the company's stock. However, Canaccord Genuity adjusted its financial outlook, lowering the price target to $77 from $79, while maintaining a Buy rating.
Rhythm Pharmaceuticals is also advancing with its Phase 3 study of setmelanotide in patients with hypothalamic obesity and has initiated Phase 2 trials for two new MC4R agonists, further expanding their development pipeline.
InvestingPro Insights
Rhythm Pharmaceuticals' financial metrics and market performance align with H.C. Wainwright's optimistic outlook. According to InvestingPro data, the company's revenue growth is impressive, with a 132.56% increase in the last twelve months as of Q2 2024. This robust growth supports the firm's confidence in IMCIVREE's sales potential.
InvestingPro Tips highlight Rhythm's "impressive gross profit margins," which is reflected in the data showing a gross profit margin of 88.8% for the same period. This strong margin suggests efficient cost management and potential for profitability as sales increase.
The stock's performance has been noteworthy, with InvestingPro data showing a one-year price total return of 112.28%, indicating strong market confidence. This aligns with the "high return over the last year" mentioned in the InvestingPro Tips.
While H.C. Wainwright projects losses for 2024 and 2025, it's worth noting that InvestingPro Tips indicate Rhythm "operates with a moderate level of debt" and "liquid assets exceed short term obligations," which could provide financial flexibility as the company works towards profitability.
For investors seeking more comprehensive analysis, InvestingPro offers 12 additional tips for Rhythm Pharmaceuticals, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.